Xiamei Zhang

发表

Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus

D. Ince, D. Hooper, L. C. Silver, 2003, Antimicrobial Agents and Chemotherapy.

A Novel Small-Molecule Inhibitor of Transforming Growth Factor B Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

Juswinder Singh, S. Albelda, M. Corbley, 2007 .

Recurrence after Surgical Resection and Prevents Tumor In vivo Mesothelioma Tumor Growth Type I Receptor Kinase ( SM 16 ) Inhibits Murine β Factor A Novel Small-Molecule Inhibitor of Transforming Growth

Juswinder Singh, S. Albelda, M. Corbley, 2007 .

A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts

Joshua M. Korn, W. Sellers, P. Sorger, 2020, Cancer Research.

A Mutation in the 5′ Untranslated Region Increases Stability of norA mRNA, Encoding a Multidrug Resistance Transporter of Staphylococcus aureus

Q. C. Truong-Bolduc, D. Hooper, Xiamei Zhang, 2001, Journal of bacteriology.

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models

J. Michaelson, I. Joseph, Xiamei Zhang, 2012, Cancer biology & therapy.

Characterization of NorR Protein, a Multifunctional Regulator of norA Expression in Staphylococcus aureus

Q. C. Truong-Bolduc, D. Hooper, Xiamei Zhang, 2003, Journal of bacteriology.

IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.

Christian M. Metallo, Ajit S. Divakaruni, M. V. Vander Heiden, 2014, Cancer research.

Activity of and Resistance to Moxifloxacin in Staphylococcus aureus

D. Ince, D. Hooper, Xiamei Zhang, 2003, Antimicrobial Agents and Chemotherapy.

Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone

D. Ince, D. Hooper, L. C. Silver, 2002, Antimicrobial Agents and Chemotherapy.

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.

W. Sellers, T. Hu, Vivien W. Chan, 2017, Cancer discovery.

Therapeutics , Targets , and Chemical Biology IDH 1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism

Christian M. Metallo, Ajit S. Divakaruni, M. V. Heiden, 2014 .

A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

Juswinder Singh, S. Albelda, M. Corbley, 2007 .

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

P. Hammerman, G. Caponigro, J. Engelman, 2020, Clinical Cancer Research.

A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.

Juswinder Singh, S. Albelda, M. Corbley, 2007, Cancer research.

The Use of Virtual Screening in ALK5 Kinase Inhibitor Discovery and Validation of Orally Active ALK5 Kinase Inhibitors in Oncology

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2008 .

Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

G. Cheng, L. Kaiser, S. Albelda, 2008, Cancer research.

SM16, an Orally Active TGF-&bgr; Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2008, Arteriosclerosis, thrombosis, and vascular biology.

An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.

Raymond B. Runyan, D. Besselsen, D. Mahadevan, 2009, Anticancer research.

Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts

D. Ruddy, J. Williams, D. Stuart, 2019, Molecular Cancer Therapeutics.

Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.

D. Baker, N. Pathan, D. Lindner, 2017, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts

Joshua M. Korn, W. Sellers, P. Sorger, 2020, bioRxiv.

Abstract 1680:In vitroandin vivoactivity of a highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug conjugate

T. Hu, E. Lees, Dongshu Chen, 2015 .